| Literature DB >> 23020726 |
Abstract
Although improvements in genomic technologies during the past decade have greatly advanced our understanding of the genomic alterations that contribute to lung cancer, and the disease has (to a degree) become a paradigm for individualized cancer treatment in solid tumors, additional challenges must be addressed before the goal of personalized cancer therapy can become a reality for lung cancer patients.Entities:
Mesh:
Year: 2012 PMID: 23020726 DOI: 10.5858/arpa.2012-0244-SA
Source DB: PubMed Journal: Arch Pathol Lab Med ISSN: 0003-9985 Impact factor: 5.534